
## **Roxane Paulin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8089623/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. American Journal of Physiology - Cell Physiology, 2020, 318, C1-C28.	2.1	26
2	PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 783-801.	1.1	16
3	Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 532-534.	2.5	1
4	Early Evidence for the Role of IncRNA TUG1 in Vascular Remodelling in Pulmonary Hypertension. Canadian Journal of Cardiology, 2019, 35, 1433-1434.	0.8	7
5	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circulation Research, 2018, 122, 1021-1032.	2.0	111
6	Small SeP or Giant Leap for Pulmonary Hypertension Research?. Circulation, 2018, 138, 624-626.	1.6	5
7	Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1513-1523.	1.1	72
8	Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension. Pulmonary Circulation, 2017, 7, 572-587.	0.8	15
9	The cancer theory of pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 285-299.	0.8	154
10	HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension. Scientific Reports, 2017, 7, 4546.	1.6	70
11	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	2.5	88
12	Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase. European Urology, 2016, 69, 734-744.	0.9	66
13	Addressing Complexity in Pulmonary Hypertension. Circulation Research, 2015, 116, 1732-1735.	2.0	4
14	Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation, 2015, 132, 932-943.	1.6	173
15	A miR-208–Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension. Circulation Research, 2015, 116, 56-69.	2.0	101
16	Role for DNA Damage Signaling in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 786-797.	1.6	211
17	The Metabolic Theory of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 148-164.	2.0	244
18	Sirtuin 3 Deficiency Is Associated with Inhibited Mitochondrial Function and Pulmonary Arterial Hypertension in Rodents and Humans. Cell Metabolism, 2014, 20, 827-839.	7.2	170

**ROXANE PAULIN** 

#	ARTICLE	IF	CITATIONS
19	A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation. Cell, 2014, 158, 84-97.	13.5	463
20	STAT3 signaling in pulmonary arterial hypertension. Jak-stat, 2012, 1, 223-233.	2.2	72
21	From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. Journal of Molecular Medicine, 2011, 89, 1089-101.	1.7	45
22	Signal Transducers and Activators of Transcription-3/Pim1 Axis Plays a Critical Role in the Pathogenesis of Human Pulmonary Arterial Hypertension. Circulation, 2011, 123, 1205-1215.	1.6	156
23	Role for miR-204 in human pulmonary arterial hypertension. Journal of Experimental Medicine, 2011, 208, 535-548.	4.2	487
24	Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1798-H1809.	1.5	114